Table 1

Demographics and clinical characteristics at baseline, and split by disability progression status at 5 and 10-year follow-up

Baseline
n=81
5-year follow-up
n=67
10-year follow-up
n=50
Gender, female, n (%)55 (67.1)45 (67.2)33 (66)
Age in years, mean (SD)42 (9.5)41 (9.5)41 (9)
Disease duration in months, mean (SD)100 (88)101 (96)105 (100)
EDSS,
median (range), IQR
3.5 (0–6.0)
1.5
3.5 (0–6.0)
1.5
3.5 (0–6.0)
1.5
Disease course, n (%)
 RRMS62 (76.5)55 (82.1)43 (86)
 SPMS11 (13.6)8 (11.9)4 (8)
 PPMS8 (9.9)4 (6)3 (6)
Patients on DMT n (%)11 (13.4)9 (13.4)8 (16.3)
DMT type, n (%)
 None70 (86.6)58 (86.6)42 (84)
 Interferon β9 (11)8 (11.9)7 (14)
 Glatiramer acetate2 (2.4)1 (1.5)1 (4)
 Mitoxantrone000
 Natalizumab000
 Other000
  • Disability progression was measured using the EDSS. The differences in demographics between the disability progressing and non-progressing groups were calculated using χ2, Student t test and Mann–Whitney rank sum tests, as appropriate.

  • DMT, disease modifying treatment; EDSS, Expanded Disability Status Scale; MS, multiple sclerosis; PP, primary progressive; RR, relapsing remitting; SP, secondary progressive.